JP2002534520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002534520A5 JP2002534520A5 JP2000593605A JP2000593605A JP2002534520A5 JP 2002534520 A5 JP2002534520 A5 JP 2002534520A5 JP 2000593605 A JP2000593605 A JP 2000593605A JP 2000593605 A JP2000593605 A JP 2000593605A JP 2002534520 A5 JP2002534520 A5 JP 2002534520A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disorders
- disease
- formula
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000022821 personality disease Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- -1 pyrazinyl Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19900811 | 1999-01-12 | ||
| DE19900811.6 | 1999-01-12 | ||
| PCT/EP2000/000176 WO2000042037A1 (de) | 1999-01-12 | 2000-01-12 | Triazolverbindungen mit dopamin-d3-rezeptoraffinität |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002534520A JP2002534520A (ja) | 2002-10-15 |
| JP2002534520A5 true JP2002534520A5 (https=) | 2010-09-16 |
| JP4615125B2 JP4615125B2 (ja) | 2011-01-19 |
Family
ID=7894006
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000593605A Expired - Fee Related JP4615125B2 (ja) | 1999-01-12 | 2000-01-12 | ドーパミン−ｄ３−レセプター親和性を有するトリアゾール化合物 |
| JP2000593606A Ceased JP2002534521A (ja) | 1999-01-12 | 2000-01-12 | ドーパミン−３−レセプター親和性を有するトリアゾール化合物 |
| JP2000593604A Expired - Fee Related JP4933694B2 (ja) | 1999-01-12 | 2000-01-12 | ドーパミン−ｄ３−レセプター親和性を有するトリアゾール化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000593606A Ceased JP2002534521A (ja) | 1999-01-12 | 2000-01-12 | ドーパミン−３−レセプター親和性を有するトリアゾール化合物 |
| JP2000593604A Expired - Fee Related JP4933694B2 (ja) | 1999-01-12 | 2000-01-12 | ドーパミン−ｄ３−レセプター親和性を有するトリアゾール化合物 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6602867B1 (https=) |
| EP (3) | EP1144405B1 (https=) |
| JP (3) | JP4615125B2 (https=) |
| KR (3) | KR100775720B1 (https=) |
| CN (3) | CN1267430C (https=) |
| AR (3) | AR022230A1 (https=) |
| AT (3) | ATE366729T1 (https=) |
| AU (3) | AU2289700A (https=) |
| BG (2) | BG65105B1 (https=) |
| BR (2) | BR0007500A (https=) |
| CA (3) | CA2359948C (https=) |
| CO (3) | CO5150182A1 (https=) |
| CZ (2) | CZ20012550A3 (https=) |
| DE (3) | DE50014472D1 (https=) |
| ES (2) | ES2288839T3 (https=) |
| HK (1) | HK1045311B (https=) |
| HR (1) | HRP20010590A2 (https=) |
| HU (2) | HUP0200709A3 (https=) |
| ID (2) | ID29552A (https=) |
| IL (3) | IL144136A0 (https=) |
| NO (2) | NO20013444L (https=) |
| NZ (2) | NZ512830A (https=) |
| PL (2) | PL201889B1 (https=) |
| SK (2) | SK9862001A3 (https=) |
| TR (2) | TR200102026T2 (https=) |
| TW (1) | TWI274750B (https=) |
| WO (3) | WO2000042036A1 (https=) |
| ZA (2) | ZA200106584B (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| WO2000021951A1 (en) | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| EP1335915B1 (en) | 2000-11-14 | 2008-01-02 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| JP2005518414A (ja) * | 2001-12-21 | 2005-06-23 | スミスクライン ビーチャム パブリック リミテッド カンパニー | ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用 |
| US7314937B2 (en) * | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
| AR040126A1 (es) | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
| DE10304870A1 (de) | 2003-02-06 | 2004-08-19 | Abbott Gmbh & Co. Kg | Triazolverbindungen und ihre therapeutische Verwendung |
| ATE397755T1 (de) * | 2003-03-17 | 2008-06-15 | Bayer Healthcare Ag | Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten |
| US6919342B2 (en) | 2003-06-05 | 2005-07-19 | Abbott Gmbh & Co. Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| WO2005051945A1 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar |
| KR20050054084A (ko) * | 2003-12-03 | 2005-06-10 | 한국전자통신연구원 | 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법 |
| PT1745040E (pt) | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| JP2007527890A (ja) * | 2004-03-08 | 2007-10-04 | グラクソ グループ リミテッド | ドーパミンｄ３受容体のモジュレーター（抗精神病剤）としてのテトラヒドロベンゾアゼピン誘導体 |
| WO2005090320A2 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | Triazole derivatives and method of using the same to treat hiv infections |
| GB0412314D0 (en) | 2004-06-02 | 2004-07-07 | Glaxo Group Ltd | Compounds |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| GB0413879D0 (en) * | 2004-06-21 | 2004-07-21 | Glaxo Group Ltd | Compounds |
| GB0414795D0 (en) * | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Compounds |
| ES2340941T3 (es) | 2004-08-09 | 2010-06-11 | ABBOTT GMBH & CO. KG | Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina. |
| EP1784390A2 (en) * | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
| BRPI0518823A2 (pt) | 2004-12-02 | 2008-12-09 | Abbott Gmbh & Co Kg | compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina |
| GB0507602D0 (en) | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) * | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (en) * | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Novel compounds |
| JP5118039B2 (ja) | 2005-08-18 | 2013-01-16 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| US7799815B2 (en) | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
| WO2007028145A2 (en) * | 2005-09-02 | 2007-03-08 | Dara Biosciences, Inc. | Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system |
| US20070293548A1 (en) * | 2006-03-31 | 2007-12-20 | Wang Eric Y | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases |
| PL2118077T3 (pl) * | 2007-02-08 | 2015-05-29 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| WO2010017545A2 (en) | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US9227944B2 (en) | 2008-10-10 | 2016-01-05 | Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China | Dopamine D3 receptor ligands and preparation and medical uses of the same |
| CN102264733B (zh) | 2008-10-10 | 2014-07-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 新型多巴胺d3受体配体，其制备方法及其医药用途 |
| US9326955B2 (en) * | 2008-10-31 | 2016-05-03 | Loyola University Chicago | Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions |
| EP2792678A1 (en) * | 2009-12-22 | 2014-10-22 | Cephalon, Inc. | Tricyclic derivatives and their pharmaceutical use and compositions |
| JPWO2012124744A1 (ja) * | 2011-03-14 | 2014-07-24 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| PE20142366A1 (es) * | 2012-05-30 | 2015-01-10 | Hoffmann La Roche | Compuestos triazolo como inhibidores de pde 10 |
| RU2561063C1 (ru) * | 2014-07-01 | 2015-08-20 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | Способ коррекции неврологических нарушений при хронической алкогольной интоксикации |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
| EP3189048B1 (en) | 2014-09-03 | 2021-03-17 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
| GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| EP3634406B1 (en) * | 2017-05-12 | 2023-09-06 | Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
| US10941153B2 (en) * | 2018-05-31 | 2021-03-09 | Regents Of The University Of Minnesota | Substituted phenethylamine derivatives |
| GB202117129D0 (en) * | 2021-11-26 | 2022-01-12 | Epidarex Exeed Ltd | Compounds |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4408049A (en) | 1980-09-17 | 1983-10-04 | The Upjohn Company | Substituted piperazinyl-1,2,4-triazoles |
| US4338453A (en) * | 1980-09-17 | 1982-07-06 | The Upjohn Company | Aminoalkyl-1,2,4-triazoles |
| US4577020A (en) * | 1983-01-25 | 1986-03-18 | The Upjohn Company | Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents |
| FR2601952B1 (fr) | 1986-07-23 | 1988-11-25 | Carpibem | Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques |
| AU644500B2 (en) * | 1990-12-20 | 1993-12-09 | Merrell Dow Pharmaceuticals Inc. | 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma |
| JP3155276B2 (ja) | 1991-05-20 | 2001-04-09 | ファルマシア・アンド・アップジョン・カンパニー | カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体 |
| HUT67665A (en) | 1991-11-05 | 1995-04-28 | Smithkline Beckman Corp | Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them |
| FR2687146B1 (fr) | 1992-02-12 | 1994-04-01 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| EP0699069B9 (en) | 1993-04-27 | 2003-10-22 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| DE4338396A1 (de) * | 1993-11-10 | 1995-05-11 | Basf Ag | N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| FR2722194B1 (fr) | 1994-07-06 | 1996-08-23 | Adir | Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent |
| DE4425144A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
| EP0793653A1 (en) * | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| AU5147196A (en) | 1995-03-27 | 1996-10-16 | Smithkline Beecham Plc | Bicyclic amine derivatives and their use as anti-psychotic a gents |
| AU5272296A (en) * | 1995-04-06 | 1996-10-23 | Novo Nordisk A/S | Benzopyranopyrrole compounds, their preparation and use |
| GB9518572D0 (en) | 1995-09-12 | 1995-11-15 | Smithkline Beecham Plc | Compounds |
| AU7490496A (en) * | 1995-11-10 | 1997-05-29 | Novo Nordisk A/S | Enantiomers of cis-benz{e}indole compounds, their preparation and utility as dopamine-d3 receptor selective agents |
| FR2742149B1 (fr) * | 1995-12-11 | 1998-02-13 | Inst Nat Sante Rech Med | Nouveaux derives de 2-naphtamides et leurs applications therapeutiques |
| DE19600934A1 (de) * | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
| US5688950A (en) | 1996-04-23 | 1997-11-18 | Neurogen Corporation | Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands |
| WO1997043262A1 (en) * | 1996-05-11 | 1997-11-20 | Smithkline Beecham P.L.C. | Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors |
| ES2205227T3 (es) * | 1996-05-31 | 2004-05-01 | PHARMACIA & UPJOHN COMPANY | Aminas ciclicas aril-sustituidas como ligandos selectivos de dopamina d3'. |
| GB9612153D0 (en) | 1996-06-11 | 1996-08-14 | Smithkline Beecham Plc | Compounds |
| CA2263284A1 (en) * | 1996-08-14 | 1998-02-19 | Smithkline Beecham P.L.C. | Tetrahydroisoquinoline derivatives and their pharmaceutical use |
| JPH10195056A (ja) * | 1996-11-12 | 1998-07-28 | Takeda Chem Ind Ltd | 縮合ベンゼン誘導体、その製造法および剤 |
| AU735764B2 (en) | 1996-12-06 | 2001-07-12 | Abbott Laboratories | Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds |
| FR2760014B1 (fr) * | 1997-02-27 | 1999-04-09 | Adir | Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9708694D0 (en) * | 1997-04-30 | 1997-06-18 | Smithkline Beecham Plc | Compounds |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| BR9809591A (pt) * | 1997-05-03 | 2001-09-11 | Smithkline Beecham Plc | Derivados de tetraidoisoquinolina como moduladores de receptores de dopamina d3 |
| GB9709303D0 (en) * | 1997-05-09 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| GB9710366D0 (en) * | 1997-05-20 | 1997-07-16 | Biocompatibles Ltd | Stent deployment device |
| FR2764890B1 (fr) | 1997-06-24 | 1999-08-27 | Adir | Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
-
2000
- 2000-01-10 TW TW089100271A patent/TWI274750B/zh not_active IP Right Cessation
- 2000-01-10 AR ARP000100080A patent/AR022230A1/es not_active Application Discontinuation
- 2000-01-10 AR ARP000100079A patent/AR022229A1/es not_active Application Discontinuation
- 2000-01-10 AR ARP000100078A patent/AR022228A1/es not_active Application Discontinuation
- 2000-01-12 WO PCT/EP2000/000177 patent/WO2000042036A1/de not_active Ceased
- 2000-01-12 CA CA2359948A patent/CA2359948C/en not_active Expired - Fee Related
- 2000-01-12 US US09/889,161 patent/US6602867B1/en not_active Expired - Lifetime
- 2000-01-12 DE DE50014472T patent/DE50014472D1/de not_active Expired - Lifetime
- 2000-01-12 EP EP00903574A patent/EP1144405B1/de not_active Expired - Lifetime
- 2000-01-12 CZ CZ20012550A patent/CZ20012550A3/cs unknown
- 2000-01-12 JP JP2000593605A patent/JP4615125B2/ja not_active Expired - Fee Related
- 2000-01-12 IL IL14413600A patent/IL144136A0/xx active IP Right Grant
- 2000-01-12 CA CA002359952A patent/CA2359952A1/en not_active Abandoned
- 2000-01-12 WO PCT/EP2000/000176 patent/WO2000042037A1/de not_active Ceased
- 2000-01-12 DE DE50015576T patent/DE50015576D1/de not_active Expired - Lifetime
- 2000-01-12 NZ NZ512830A patent/NZ512830A/en not_active IP Right Cessation
- 2000-01-12 PL PL349841A patent/PL201889B1/pl unknown
- 2000-01-12 SK SK986-2001A patent/SK9862001A3/sk unknown
- 2000-01-12 CN CNB008049432A patent/CN1267430C/zh not_active Expired - Fee Related
- 2000-01-12 AU AU22897/00A patent/AU2289700A/en not_active Abandoned
- 2000-01-12 EP EP00901535A patent/EP1140907B1/de not_active Expired - Lifetime
- 2000-01-12 HR HR20010590A patent/HRP20010590A2/hr not_active Application Discontinuation
- 2000-01-12 CO CO00001265A patent/CO5150182A1/es unknown
- 2000-01-12 WO PCT/EP2000/000175 patent/WO2000042038A1/de not_active Ceased
- 2000-01-12 CZ CZ20012551A patent/CZ303926B6/cs not_active IP Right Cessation
- 2000-01-12 JP JP2000593606A patent/JP2002534521A/ja not_active Ceased
- 2000-01-12 ID IDW00200101681A patent/ID29552A/id unknown
- 2000-01-12 NZ NZ512864A patent/NZ512864A/xx not_active IP Right Cessation
- 2000-01-12 AT AT00901535T patent/ATE366729T1/de not_active IP Right Cessation
- 2000-01-12 ID IDW00200101733A patent/ID29930A/id unknown
- 2000-01-12 BR BR0007500-0A patent/BR0007500A/pt not_active Application Discontinuation
- 2000-01-12 AT AT00902583T patent/ATE424398T1/de not_active IP Right Cessation
- 2000-01-12 CA CA002359942A patent/CA2359942A1/en not_active Abandoned
- 2000-01-12 CN CNB008049424A patent/CN1149209C/zh not_active Expired - Fee Related
- 2000-01-12 AU AU24367/00A patent/AU773047B2/en not_active Ceased
- 2000-01-12 KR KR1020077004587A patent/KR100775720B1/ko not_active Expired - Fee Related
- 2000-01-12 KR KR1020017008780A patent/KR100730667B1/ko not_active Expired - Fee Related
- 2000-01-12 CN CN00804933A patent/CN1347414A/zh active Pending
- 2000-01-12 AU AU25412/00A patent/AU772948B2/en not_active Ceased
- 2000-01-12 HU HU0200709A patent/HUP0200709A3/hu unknown
- 2000-01-12 AT AT00903574T patent/ATE449768T1/de not_active IP Right Cessation
- 2000-01-12 DE DE50015802T patent/DE50015802D1/de not_active Expired - Lifetime
- 2000-01-12 IL IL14413700A patent/IL144137A0/xx unknown
- 2000-01-12 TR TR2001/02026T patent/TR200102026T2/xx unknown
- 2000-01-12 ES ES00901535T patent/ES2288839T3/es not_active Expired - Lifetime
- 2000-01-12 US US09/889,163 patent/US6583166B1/en not_active Expired - Lifetime
- 2000-01-12 TR TR2001/02025T patent/TR200102025T2/xx unknown
- 2000-01-12 HU HU0200522A patent/HUP0200522A3/hu unknown
- 2000-01-12 JP JP2000593604A patent/JP4933694B2/ja not_active Expired - Fee Related
- 2000-01-12 ES ES00903574T patent/ES2334326T3/es not_active Expired - Lifetime
- 2000-01-12 CO CO00001269A patent/CO5150224A1/es unknown
- 2000-01-12 US US09/889,156 patent/US6579892B1/en not_active Expired - Lifetime
- 2000-01-12 SK SK985-2001A patent/SK9852001A3/sk unknown
- 2000-01-12 CO CO00001268A patent/CO5150227A1/es unknown
- 2000-01-12 HK HK02106847.0A patent/HK1045311B/zh not_active IP Right Cessation
- 2000-01-12 PL PL350246A patent/PL200238B1/pl unknown
- 2000-01-12 EP EP00902583A patent/EP1140908B1/de not_active Expired - Lifetime
- 2000-01-12 KR KR1020017008777A patent/KR100687682B1/ko not_active Expired - Fee Related
- 2000-01-12 BR BR0007504-3A patent/BR0007504A/pt not_active Application Discontinuation
-
2001
- 2001-07-03 IL IL144136A patent/IL144136A/en not_active IP Right Cessation
- 2001-07-11 NO NO20013444A patent/NO20013444L/no not_active Application Discontinuation
- 2001-07-11 NO NO20013443A patent/NO20013443L/no not_active Application Discontinuation
- 2001-08-03 BG BG105783A patent/BG65105B1/bg unknown
- 2001-08-03 BG BG105784A patent/BG65086B1/bg unknown
- 2001-08-10 ZA ZA200106584A patent/ZA200106584B/en unknown
- 2001-08-10 ZA ZA200106585A patent/ZA200106585B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002534520A5 (https=) | ||
| EP2821085A3 (en) | RNA interference for the treatment of gain-of-function disorders | |
| JP2003503454A5 (https=) | ||
| EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
| EP1633302A4 (en) | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION | |
| ATE524184T1 (de) | 2,4-pyrimidindiamin-verbindungen und ihre verwendungszwecke | |
| DE602006012459D1 (de) | Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a-beta-oligomere und verfahren zur herstellung dieser antikörper | |
| Klein et al. | Thyroid (neuro) myopathy. | |
| JP2005523335A5 (https=) | ||
| ZA200606834B (en) | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease | |
| DE60029929D1 (de) | VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN | |
| WO2003015780A3 (en) | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | |
| DuPont | Treatment of travelers' diarrhea. | |
| AU2003236714A8 (en) | Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio | |
| DE60200531D1 (de) | Mikroemulsionen zur transdermalen Verabreichung von Apomorphin für die Behandlung von Morbus Parkinson | |
| Linday | Saccharomyces boulardii: potential adjunctive treatment for children with autism and diarrhea. | |
| BR9916185A (pt) | Derivados de 1,4-piperazina tendo atividade receptora de 5ht1a | |
| DE60336596D1 (de) | Ortspezifische verabreichung von aktiven substanzen im darm | |
| EZZELL | Africa's Suffering. | |
| DE60327567D1 (de) | Verfahren zur herstellung von 3,3',4,4'-tetraaminobiphenyl | |
| WO2004009633A8 (en) | Serotonin receptor | |
| Reagan | The Eternal Optimist. | |
| ATE440826T1 (de) | Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen | |
| Bennion | Commentary: The freedom of informed choice. | |
| Roche et al. | Just Another Day in a Bridge Town. |